

Supplementary Material

Table S1. Changes in mTSS based on different subgroup analyses (including GC, CCP antibody, and baseline ES)

		Placebo (N=306)	Denosumab	
			Q6M (N=302)	Q3M (N=301)
Baseline SJC \geq 10	N	127	115	122
	Mean (SD)	1.43 (3.44)	1.10 (3.14)	0.76 (2.24)
	Median (Q1, Q3)	0.00 (0.00, 1.50)	0.00 (0.00, 1.00)	0.00 (0.00, 1.00)
	<i>p</i> -value	–	0.7198	0.0259
Baseline SJC <10	N	179	187	179
	Mean (SD)	1.55 (3.93)	0.74 (3.39)	0.59 (2.11)
	Median (Q1, Q3)	0.00 (0.00, 1.50)	0.00 (0.00, 0.50)	0.00 (0.00, 0.50)
	<i>p</i> -value	–	0.0006	0.0023
Baseline TJC \geq 6	N	160	143	155

	Mean (SD)	1.77 (4.26)	1.09 (3.37)	0.88 (2.66)
	Median (Q1, Q3)	0.00 (0.00, 2.00)	0.00 (0.00, 1.00)	0.00 (0.00, 1.00)
	<i>p</i> -value	–	0.0083	0.0027
Baseline TJC 3–5	N	46	67	63
	Mean (SD)	1.56 (3.46)	1.03 (4.30)	0.36 (1.44)
	Median (Q1, Q3)	0.00 (0.00, 1.00)	0.00 (0.00, 1.07)	0.00 (0.00, 0.00)
	<i>p</i> -value	–	0.6393	0.0152
Baseline TJC \leq 2	N	100	92	83
	Mean (SD)	1.04 (2.82)	0.43 (2.12)	0.46 (1.44)
	Median (Q1, Q3)	0.00 (0.00, 1.00)	0.00 (0.00, 0.50)	0.00 (0.00, 0.50)
	<i>p</i> -value	–	0.0798	0.2881
Baseline CRP \geq 1.0 mg/dL	N	44	56	38
	Mean (SD)	3.34 (6.47)	2.49 (5.72)	2.49 (4.14)
	Median	1.00 (0.00, 3.25)	0.50 (0.00, 2.13)	1.18 (0.00, 3.81)

	(Q1, Q3)			
	<i>p</i> -value	–	0.3339	0.7377
Baseline CRP <1.0	N	262	246	263
mg/dL	Mean (SD)	1.19 (2.95)	0.51 (2.30)	0.39 (1.54)
	Median	0.00 (0.00, 1.13)	0.00 (0.00, 0.50)	0.00 (0.00, 0.50)
	(Q1, Q3)			
	<i>p</i> -value	–	0.0007	0.0001
Baseline ESR ≥28	N	80	96	91
mm/h	Mean (SD)	2.77 (5.44)	1.89 (4.93)	1.71 (3.25)
	Median	1.00 (0.00, 3.00)	0.25 (0.00, 2.00)	0.50 (0.00, 2.50)
	(Q1, Q3)			
	<i>p</i> -value	–	0.1760	0.2472
Baseline ESR <28	N	226	206	210
mm/h	Mean (SD)	1.05 (2.77)	0.41 (2.00)	0.20 (1.21)
	Median	0.00 (0.00, 1.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)
	(Q1, Q3)			

	<i>p</i> -value	–	0.0018	<0.0001
Glucocorticoid use present	N	106	109	106
	Mean (SD)	1.97 (4.78)	0.82 (3.25)	0.53 (1.47)
	Median (Q1, Q3)	0.00 (0.00, 2.00)	0.00 (0.00, 1.00)	0.00 (0.00, 0.50)
	<i>p</i> -value	–	0.0169	0.0123
Glucocorticoid use absent	N	200	193	195
	Mean (SD)	1.25 (3.01)	0.91 (3.34)	0.73 (2.46)
	Median (Q1, Q3)	0.00 (0.00, 1.50)	0.00 (0.00, 0.50)	0.00 (0.00, 0.50)
	<i>p</i> -value	–	0.0445	0.0046
RF status positive	N	197	199	184
	Mean (SD)	1.94 (4.35)	1.08 (3.75)	0.99 (2.60)
	Median (Q1, Q3)	0.50 (0.00, 2.00)	0.00 (0.00, 1.00)	0.00 (0.00, 1.43)

	<i>p</i> -value	–	0.0072	0.0048
RF status negative	N	109	103	117
	Mean (SD)	0.70 (1.99)	0.50 (2.14)	0.13 (0.99)
	Median (Q1, Q3)	0.00 (0.00, 0.50)	0.000 (0.00, 0.00)	0.000 (0.000, 0.00)
	<i>p</i> -value	–	0.0722	0.0230
Anti-CCP antibody positive	N	211	228	213
	Mean (SD)	2.10 (4.33)	1.15 (3.69)	0.89 (2.49)
	Median (Q1, Q3)	0.50 (0.00, 2.50)	0.00 (0.00, 1.16)	0.00 (0.00, 1.00)
	<i>p</i> -value	–	0.0008	<0.0001
Anti-CCP antibody negative	N	95	74	88
	Mean (SD)	0.16 (0.82)	0.03 (1.26)	0.10 (0.77)
	Median (Q1, Q3)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)
	<i>p</i> -value	–	0.1193	0.5763

Baseline mTSS ≥6.5	N	140	165	157
	Mean (SD)	2.42 (4.98)	1.51 (4.32)	1.14 (2.80)
	Median (Q1, Q3)	0.50 (0.00, 3.00)	0.00 (0.00, 1.50)	0.00 (0.00, 1.50)
	<i>p</i> -value	.	0.0748	0.0245
Baseline mTSS <6.5	N	166	137	144
	Mean (SD)	0.72 (1.86)	0.12 (0.70)	0.13 (0.84)
	Median (Q1, Q3)	0.00 (0.00, 1.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)
	<i>p</i> -value	.	0.0002	<.0001
Baseline ES ≥3.5	N	140	168	169
	Mean (SD)	2.44 (4.99)	1.36 (4.16)	1.02 (2.77)
	Median (Q1, Q3)	0.50 (0.00, 3.25)	0.00 (0.00, 1.50)	0.00 (0.00, 1.36)
	<i>p</i> -value	.	0.0345	0.0034
Baseline ES <3.5	N	166	134	132
	Mean (SD)	0.70 (1.83)	0.28 (1.49)	0.19 (0.70)
	Median (Q1, Q3)	0.00 (0.00, 1.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)
	<i>p</i> -value	.	0.0007	0.0012

CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ES, bone erosion score; ESR, erythrocyte sedimentation rate; mTSS, modified total Sharp score; Q3M, denosumab 60 mg every 3 months; Q6M, denosumab 60 mg every 6 months; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count.